Modality
ADC
MOA
MDM2i
Target
WRN
Pathway
NF-κB
BCCMCL
Development Pipeline
Preclinical
~Mar 2017
→ ~Jun 2018
Phase 1
Sep 2018
→ Mar 2028
Phase 1Current
NCT08238537
2,678 pts·BCC
2018-09→2027-09·Not yet recruiting
NCT04027615
524 pts·MCL
2019-02→2028-03·Completed
3,202 total pts2 indications
Phase 2
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-09-141.5y awayPh2 Data· BCC
2028-03-232.0y awayPh2 Data· MCL
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2
P1/2
Not yet…
P1/2
Complet…
Catalysts
Ph2 Data
2027-09-14 · 1.5y away
BCC
Ph2 Data
2028-03-23 · 2.0y away
MCL
CompletedNot yet recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT08238537 | Phase 1/2 | BCC | Not yet recr... | 2678 | DOR |
| NCT04027615 | Phase 1/2 | MCL | Completed | 524 | PANSS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| Doxacapivasertib | Eli Lilly | Phase 3 | APOC3 | |
| MRK-3745 | Merck & Co | Phase 2 | WRN | |
| Zorisotorasib | AstraZeneca | Phase 1 | WRN | |
| BMY-3371 | Bristol-Myers Squibb | Phase 3 | WRN | |
| BMY-8678 | Bristol-Myers Squibb | Approved | RET | |
| Lisorapivir | Takeda | Preclinical | WRN | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| AMG-415 | Amgen | Phase 1 | CDK2 | |
| GIL-2037 | Gilead Sciences | Approved | KRASG12D | |
| Capiglumide | BioNTech | Preclinical | CGRP |